Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04138277 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)
A Phase 3 study, sponsored by Amicus Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 119
- Enrollment target
NCT04138277 is a Phase 3 study that has completed, run by Amicus Therapeutics. The registered enrollment target is 119 participants.
The verdict
NCT04138277, a Phase 3 study, has completed, sponsored by Amicus Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 119 participants
- Enrollment target
Study Summary
This is a multicenter, international open-label extension study of ATB200/AT2221 in adult subjects with late-onset Pompe disease (LOPD) who completed Study ATB200-03.
Interventions
- DRUG AT2221
- BIOLOGICAL ATB200
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2019-12-18 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04138277
The ClinicalTrials.gov registry entry for NCT04138277 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amicus Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AT2221 is the first listed.
NCT04138277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04138277 about?
NCT04138277 is a clinical study titled "A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)". This is a multicenter, international open-label extension study of ATB200/AT2221 in adult subjects with late-onset Pompe disease (LOPD) who completed Study ATB200-03.
What is the current status of trial NCT04138277?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 119 participants. The study started on 2019-12-18. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT04138277?
The interventions under investigation include: AT2221 (DRUG), ATB200 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04138277?
This trial is sponsored by Amicus Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.